Literature DB >> 12918602

Metabolic consequences of atypical antipsychotic drugs.

Harold E Lebovitz1.   

Abstract

Atypical antipsychotic drugs have become the treatment of choice for psychotic disorders. However, these medications, though certainly superior in many respects to the more traditional medications, have been shown to have a number of untoward consequences. Understanding of the metabolic consequences of these medications is essential for the psychiatrist. The possible development of diabetes, weight gain, and hypertriglyceridemia in patients taking atypical antipsychotics makes it imperative that the prescribing physician regularly monitor patients on these agents. One possible monitoring scheme is outlined and recommendations for treatment are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918602     DOI: 10.1023/a:1024170622266

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  42 in total

1.  Diabetic ketoacidosis with olanzapine treatment.

Authors:  B Gatta; V Rigalleau; H Gin
Journal:  Diabetes Care       Date:  1999-06       Impact factor: 19.112

Review 2.  New onset diabetes and atypical antipsychotics.

Authors:  K A Liebzeit; J S Markowitz; C F Caley
Journal:  Eur Neuropsychopharmacol       Date:  2001-02       Impact factor: 4.600

Review 3.  Hyperglycemia and antipsychotic medications.

Authors:  D W Haupt; J W Newcomer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

4.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

5.  Potentiation of insulin secretion in vitro by serotonin antagonists.

Authors:  J M Feldman; K E Quickel; H E Lebovitz
Journal:  Diabetes       Date:  1972-07       Impact factor: 9.461

6.  Olanzapine increases weight and serum triglyceride levels.

Authors:  D N Osser; D M Najarian; R L Dufresne
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

Review 7.  Weight gain associated with neuroleptic medication: a review.

Authors:  J M Stanton
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

8.  Beta cell monoamines: further evidence for their role in modulating insulin secretion.

Authors:  J P Wilson; R W Downs; J M Feldman; H E Lebovitz
Journal:  Am J Physiol       Date:  1974-08

9.  Risperidone-associated new-onset diabetes.

Authors:  D A Wirshing; J M Pierre; J Eyeler; J Weinbach; W C Wirshing
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

10.  Fatality from olanzapine induced hyperglycemia.

Authors:  Robert Meatherall; John Younes
Journal:  J Forensic Sci       Date:  2002-07       Impact factor: 1.832

View more
  7 in total

Review 1.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Circadian-timed dopamine agonist treatment reverses high-fat diet-induced diabetogenic shift in ventromedial hypothalamic glucose sensing.

Authors:  Carl R Stoelzel; Yahong Zhang; Anthony H Cincotta
Journal:  Endocrinol Diabetes Metab       Date:  2020-05-07

3.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

4.  Circulating dopamine and C-peptide levels in fasting nondiabetic hypertensive patients: the Graz Endocrine Causes of Hypertension study.

Authors:  Andreas Tomaschitz; Eberhard Ritz; Katharina Kienreich; Burkert Pieske; Winfried März; Bernhard O Boehm; Christiane Drechsler; Andreas Meinitzer; Stefan Pilz
Journal:  Diabetes Care       Date:  2012-06-14       Impact factor: 19.112

Review 5.  Tic disorders: from pathophysiology to treatment.

Authors:  Liborio Rampello; Alessandro Alvano; Giuseppe Battaglia; Valeria Bruno; Rocco Raffaele; Francesco Nicoletti
Journal:  J Neurol       Date:  2005-12-05       Impact factor: 6.682

6.  Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance.

Authors:  Fabio Panariello; Giuseppe Perruolo; Angela Cassese; Ferdinando Giacco; Ginevra Botta; Alessia P M Barbagallo; Giovanni Muscettola; Francesco Beguinot; Pietro Formisano; Andrea de Bartolomeis
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

7.  Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.

Authors:  Stan Kutcher; Sarah J Brooks; David M Gardner; Bill Honer; Lili Kopala; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Jorge Soni; Richard Williams
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.